Estradiol/drospirenone

Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women.^[1][2][3] It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet.^[1] The medication was approved in the United States in 2005.^[1] It is marketed widely throughout the world.^[4]

Estradiol/drospirenone

Estradiol
Drospirenone
Combination of
Estradiol	Estrogen
Drospirenone	Progestogen; Progestin; Antimineralocorticoid; Antiandrogen
Clinical data
Trade names	Angeliq
Other names	E2/DRSP; BAY-864891
Routes of administration	By mouth
Drug class	Estrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
Legal status
Legal status	US: ℞-only
Identifiers
CAS Number	350818-73-4

See also

• Estetrol/drospirenone
• Ethinylestradiol/drospirenone
• Ethinylestradiol/drospirenone/levomefolic acid
• Ethinylestradiol/drospirenone/prasterone
• List of combined sex-hormonal preparations § Estrogens and progestogens